Display Settings:

Format

Send to:

Choose Destination

    J Consult Clin Psychol. 2008 Dec;76(6):1076-82.

    Serious adverse events in randomized psychosocial treatment studies: safety or arbitrary edicts?

    Petry NM, Roll JM, Rounsaville BJ, Ball SA, Stitzer M, Peirce JM, Blaine J, Kirby KC, McCarty D, Carroll KM.

    Calhoun Cardiology Center, Department of Medicine, University of Connecticut Health Center, USA. petry@psychiatry.uchc.edu

    Human subjects protection policies developed for pharmaceutical trials are now being widely applied to psychosocial intervention studies. This study examined occurrences of serious adverse events (SAEs) reported in multicenter psychosocial trials of the National Institute on Drug Abuse Clinical Trials Network. Substance-abusing participants (N = 1,687) were randomized to standard care or standard care plus either contingency management or motivational enhancement. Twelve percent of participants experienced 1 or more SAEs during the 27,198 person-weeks of follow-up. Of the 260 SAEs recorded, none were judged by the data safety monitoring board to be study related, and there were no significant differences between experimental and control conditions in SAE incidence rates. These data underscore the need to reconsider the rationale behind, and appropriate methods for, monitoring safety during psychosocial therapy trials.

    PMID: 19045975 [PubMed - indexed for MEDLINE]

    PMCID: PMC2756150

    Publication Types, MeSH Terms, Substances, Grant Support

    Publication Types:

    MeSH Terms:

    Substances:

    Grant Support:

    Supplemental Content

    Click here to read Click here to read

    Patient drug information

    • Methadone (Dolophine®, Methadose®, Methadose® Oral Concentrate)

      Methadone is used to relieve moderate to severe pain that has not been relieved by non-narcotic pain relievers. It also is used to prevent withdrawal symptoms in patients who were addicted to opiate drugs and are enrolle...